Capecitabine and Gemcitabine in Treating Patients With Metastatic Kidney Cancer
Study Information
Alliance Study ID: CALGB-90008
NCT Study ID (ClinicalTrials.gov): NCT00042965
Alliance Committee: Genitourinary Cancer
Disease or Cancer Type: Genitourinary Cancers – Kidney / Bladder / Urothelial / Testicular
Alliance Study Chair: Walter M. Stadler, MD, FACP
Status: COMPLETED
Study Description
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combining capecitabine with gemcitabine in treating patients who have metastatic kidney cancer.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information